It’s actually quite an interesting question, because in hindsight, after the publication of ORIENTAL-MeVO, the motivation for this analysis appears to be more clear, because that study showed a benefit of thrombectomy, and it happened to have less patients receiving intravenous thrombolysis than patients with more severe stroke at admission. But actually, our pre-specified analysis was planned before the presentation of the first results of ORIENTAL-MeVO...
It’s actually quite an interesting question, because in hindsight, after the publication of ORIENTAL-MeVO, the motivation for this analysis appears to be more clear, because that study showed a benefit of thrombectomy, and it happened to have less patients receiving intravenous thrombolysis than patients with more severe stroke at admission. But actually, our pre-specified analysis was planned before the presentation of the first results of ORIENTAL-MeVO. So we still didn’t know that. And what we knew was that for all the three trials that were negative at the time, there were a large number of patients with mild, very mild symptoms with low NIHSS at admission. And our biological thinking was that intravenous thrombolysis we know has a higher rate of recanalization for patients with small vessel occlusions. And therefore, in these patients, the benefit of thrombectomy, if you have very small symptoms and you already have access to intravenous thrombolysis, there may not be too much for endovascular thrombectomy to do. And on the other hand, these patients might have a higher risk of bleeding because you already have the thrombolytic and you need to do a thrombectomy in a smaller vessel that’s more mobile, more fragile, more distal. So that was the rationale for the study.
You also asked me what did we find. So the primary analysis, we looked at what are patients that didn’t have a minor stroke, so patients with an NIHSS of at least six or higher. If in this group, patients who did not receive intravenous thrombolysis had better benefit of thrombectomy when compared to patients who did receive intravenous thrombolysis. We did not find a statistically significant interaction, but the point estimates were compatible with our primary hypothesis. And again, this is a secondary post-hoc analysis in a small group of patients. So it’s potentially underpowered to explore treatment effect modification. We also did a secondary analysis in which we looked only at patients who are not eligible for intravenous thrombolysis. And then instead of using the more traditional definition of minor stroke, we looked at the whole NIHSS spectrum and tried to determine whether patients who had a more severe NIHSS admission, if they would benefit from thrombectomy as long as they were not eligible for intravenous thrombolysis. And in these analyses, we found a statistically significant strong interaction showing that patients who had a higher NIHSS admission and were not eligible for IVT, they appeared to benefit from thrombectomy. But again, this was a post-hoc analysis in a small subgroup. It’s very biologically plausible. It was pre-specified a priori. It’s compatible with the results of ORIENTAL-MeVO, of what we understand about the pathophysiology of stroke in small medium vessel occlusions. But this is not yet a clinical decision rule so this is more in the domain of a hypothesis generating data and what I think is important is that it shows us a clear group on which there might be benefit but we need to get more data either by combining, pulling the data of all the trials that have been done in a large individual participant data meta-analysis, and even more, by randomizing more patients for subsequent trials on distal medium vessel occlusions.
As much as I would like to say that these results show a clear treatment decision rule and that they should inform what the clinicians should do, I think it’s very important that we take a step back and realize that this is a post-hoc analysis of a small subgroup of patients from one single trial. And therefore, I don’t think this is yet a rule for clinical decision making. It’s important to take into consideration. It’s also something that I think most clinicians already do take into consideration. A very severe stroke is actually the reason why most of these trials didn’t include patients with very severe stroke is that many clinicians felt these patients already had a clear benefit of thrombectomy and what I think is important is that what we see now is that we don’t really know that for sure and in fact what I think this result shows that there is more space to actually randomize more patients, to get more precision, to get a more definitive answer and to identify the patients who truly benefit and also the patients who potentially may be harmed because if you have very little tissue to be saved and very mild symptoms and you already have access to thrombolysis, maybe there is not too much benefit to be gained from thrombectomy. It’s important to determine that either in a large individual participant data meta-analysis or in a subsequent trial powered for that analysis so that we have a confirmatory result that can then be translated into clinical guidelines. I think our results are very motivating. It’s nice to see because it’s very consistent with our biological understanding of stroke, but it’s important for clinicians to not take the result of a certain threshold above 10 or below 10 in NIHSS as an established clinical rule because I think we are not there yet.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.